Clinical Trials

15 enrolled

Melanoma

NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

BreastCNSDermatologicOther hematologic neoplasmThoracic

8 enrolled 13 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04971499 2026-02-20

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

26 enrolled

Melanoma

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

DermatologicHead & NeckThoracic

15 enrolled

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT07410494 2026-02-18

SELECT-CAR-NK

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

85 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

DermatologicGenitourinaryHead & NeckThoracic

18 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT00626860 2026-01-23

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

20 enrolled

Melanoma

NCT00508443 2026-01-15

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

BreastDermatologicGastrointestinalLymphoidSarcomaThoracic

150 enrolled

Urogenital Diseases, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasms, Sarcoma, Spinal Diseases, Spinal Neoplasms

NCT03829254 2026-01-12

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

135 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT05588453 2026-01-12

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04129515 2026-01-02

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Phase 1/2 Withdrawn

Melanoma

NCT03993678 2025-12-30

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

28 enrolled

DermatologicSarcoma

Melanoma, Sarcoma

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

47 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT03131908 2025-12-15

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

27 enrolled

Melanoma

NCT05089370 2025-12-08

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

8 enrolled

Melanoma

NCT06194929 2025-12-03

DETERMINE

33 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

109 enrolled

Uveal Melanoma, Melanoma

NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

34 enrolled 18 charts

Melanoma

NCT04074967 2025-11-06

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

DermatologicGenitourinaryHead & NeckThoracic

70 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06814496 2025-10-09

RABBIT

CNSDermatologicGenitourinaryGynecologicThoracic

Sinonasal undifferentiated carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Glioblastoma, Melanoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory

NCT00722228 2025-10-02

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

50 enrolled

Breast Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01898039 2025-10-02

Modified Vaccine for High Risk or Low Residual Melanoma Patients

50 enrolled

Melanoma, Neoplasm, Residual

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

BreastCNSDermatologicGynecologicSarcomaThoracic

3 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT03949153 2025-10-01

CRIRIN

19 enrolled

Melanoma

NCT07193966 2025-09-26

NG2 and DLL3 CAR-T Cells Targeting Melanoma

100 enrolled

Phase 1/2 Enrolling by invitation

Melanoma

NCT05893654 2025-09-15

MELCOM

10 enrolled

Uveal Melanoma, Melanoma

NCT06739226 2025-09-09

Combination Immunotherapy Targeting Melanoma

Melanoma

NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

81 enrolled

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02836548 2025-07-10

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

33 enrolled

Melanoma, Skin Neoplasms

NCT04464759 2025-07-08

LIMIT

94 enrolled

Melanoma

NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Phase 1/2 Suspended

47 enrolled

Melanoma

NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

DermatologicGynecologicSarcoma

15 enrolled 12 charts

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT03325101 2025-06-12

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

7 enrolled 11 charts

Melanoma

NCT03958383 2025-04-18

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

8 enrolled

Phase 1/2 Not yet recruiting

Melanoma

NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Phase 1/2 Suspended

29 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06896552 2025-03-26

Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.

60 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT04133948 2025-03-10

DONIMI

44 enrolled

Melanoma

NCT05251389 2025-03-10

FMT to Convert Response to Immunotherapy

24 enrolled

Melanoma

NCT05983237 2025-03-05

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

50 enrolled

Melanoma

NCT03047928 2025-02-20

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

48 enrolled 13 charts

Melanoma

NCT03190174 2025-02-17

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

DermatologicGastrointestinalGenitourinarySarcomaThoracic

34 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Chordoma, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Sarcoma, Ewing, Colorectal Neoplasms, Desmoid Tumors, Perivascular Epithelioid Cell Neoplasms

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

74 enrolled

Melanoma

NCT04168528 2024-12-11

Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT

13 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT02392871 2024-11-27

CombiRT

10 enrolled

Melanoma

NCT06240143 2024-11-14

MARIANE

96 enrolled

Phase 1/2 Not yet recruiting

Melanoma

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)